PURPOSE: To validate the clinical performance of two new efficient threshold-estimation procedures for frequency-doubling technology (FDT) perimetry in both visually normal individuals and patients with glaucomatous visual field loss. METHODS: Forty-one normal subjects (mean age, 48.3 +/- 11.6 years) and 50 patients with glaucomatous visual field loss (mean age, 72.7 +/- 10.0 years) were tested. Some of these participants were retested within a 3-month period. FDT perimetry was performed on a color monitor driven by a visual-stimulus-generating video board, with stimulus parameters designed to closely mimic those of the commercial FDT test. Visual field sensitivity was measured using three procedures: a modified binary search (MOBS) identical with the one used in the commercial FDT device, a rapid efficient binary search (REBS), and a procedure the uses Bayesian methods (zippy estimation of sequential testing; ZEST). The selection of optimum parameters for REBS and ZEST were based on results from previous simulations. RESULTS: Both ZEST and REBS were 40% to 50% faster than MOBS. All three methods produced similar visual field sensitivity measures, with 95% of the differences occurring between +/-2 dB for normal subjects and +/-3 dB for glaucoma patients. Test-retest performance was similar for all three procedures. CONCLUSIONS: The test time for full-threshold FDT perimetry can be approximately halved, by using either the ZEST or REBS procedure, without affecting the accuracy or reliability of the measurements. These findings in normal subjects and patients with glaucoma provide clinical confirmation of our previous investigations of these test strategies that use computer simulation.
PURPOSE: To validate the clinical performance of two new efficient threshold-estimation procedures for frequency-doubling technology (FDT) perimetry in both visually normal individuals and patients with glaucomatous visual field loss. METHODS: Forty-one normal subjects (mean age, 48.3 +/- 11.6 years) and 50 patients with glaucomatous visual field loss (mean age, 72.7 +/- 10.0 years) were tested. Some of these participants were retested within a 3-month period. FDT perimetry was performed on a color monitor driven by a visual-stimulus-generating video board, with stimulus parameters designed to closely mimic those of the commercial FDT test. Visual field sensitivity was measured using three procedures: a modified binary search (MOBS) identical with the one used in the commercial FDT device, a rapid efficient binary search (REBS), and a procedure the uses Bayesian methods (zippy estimation of sequential testing; ZEST). The selection of optimum parameters for REBS and ZEST were based on results from previous simulations. RESULTS: Both ZEST and REBS were 40% to 50% faster than MOBS. All three methods produced similar visual field sensitivity measures, with 95% of the differences occurring between +/-2 dB for normal subjects and +/-3 dB for glaucomapatients. Test-retest performance was similar for all three procedures. CONCLUSIONS: The test time for full-threshold FDT perimetry can be approximately halved, by using either the ZEST or REBS procedure, without affecting the accuracy or reliability of the measurements. These findings in normal subjects and patients with glaucoma provide clinical confirmation of our previous investigations of these test strategies that use computer simulation.
Authors: Lyne Racette; Jeffrey M Liebmann; Christopher A Girkin; Linda M Zangwill; Sonia Jain; Lida M Becerra; Felipe A Medeiros; Christopher Bowd; Robert N Weinreb; Catherine Boden; Pamela A Sample Journal: Arch Ophthalmol Date: 2010-05
Authors: Ali Tafreshi; Lyne Racette; Robert N Weinreb; Pamela A Sample; Linda M Zangwill; Felipe A Medeiros; Christopher Bowd Journal: Am J Ophthalmol Date: 2010-03 Impact factor: 5.258
Authors: Robert O Duncan; Pamela A Sample; Christopher Bowd; Robert N Weinreb; Linda M Zangwill Journal: Vision Res Date: 2012-03-29 Impact factor: 1.886
Authors: Vance Zemon; James C Tsai; Max Forbes; Lama A Al-Aswad; Chi-Ming Chen; James Gordon; Vivienne C Greenstein; George Hu; Evy C Strugstad; Elona Dhrami-Gavazi; Lawrence F Jindra Journal: Doc Ophthalmol Date: 2008-05-16 Impact factor: 2.379
Authors: Ali Tafreshi; Pamela A Sample; Jeffrey M Liebmann; Christopher A Girkin; Linda M Zangwill; Robert N Weinreb; Maziar Lalezary; Lyne Racette Journal: Invest Ophthalmol Vis Sci Date: 2008-10-31 Impact factor: 4.799
Authors: Folkert K Horn; Vicki Scharch; Christian Y Mardin; Robert Lämmer; Jan Kremers Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-02-17 Impact factor: 3.117